Matthew Hellmann

Matthew Hellmann at MSK has made important contributions to clinical immunotherapy, particularly establishing nivolumab-ipilimumab combination therapy in NSCLC (CheckMate 227) and advancing tumor mutational burden (TMB) as a predictive biomarker for checkpoint combination therapy. His work defining patient populations most likely to benefit from IO combinations and his research on mechanisms of resistance to combination checkpoint blockade have shaped the IO combinations field.